Hematopoietic progenitor kinase 1 (HPK1) plays a relevant role in regulating T-cell, B-cell and dendritic cell function. As its inactivation both in vitro and in vivo contributes to tumor growth inhibition, HPK1 is considered a therapeutic target to explore in cancer immunotherapy.
Trueline Therapeutics Inc. and Broad Institute Inc. have reported preclinical data for the novel myeloid cell leukemia 1 (MCL1) inhibitor, BRD-810, being developed for the treatment of cancer.
Itheos Therapeutics Inc. recently presented the discovery of a first-in-class, potent and selective ENT1 inhibitor, EOS-984 (EOS-301984), for the treatment of solid tumors. Immune checkpoint inhibitors (ICIs) have become essential in treating solid tumors, but only a limited number of patients currently benefit from approved ICIs.
Aging is part of the life cycle and, although the effects are not manifest until after adulthood, it actually occurs from birth. The concept of senescence has traditionally been associated with aging. However, an embryo has senescent cells. In that case, what is aging, how can it be measured, and from what point in the life cycle?
The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note that we have added three critical tables, which are continuously updated:
Korean Research Institute of Bioscience and Biotechnology and Korea Research Institute of Chemical Technology have jointly developed molecular glue degraders acting as zinc finger protein Helios (IKZF2) degradation inducers. They are described as potentially useful for the treatment of cancer.
An Uppthera Inc. patent describes new proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase-binding moiety covalently linked to a serine/threonine-protein kinase PLK1 (STPK13)-targeting moiety; they are reported to be useful for the treatment of cancer and neurological disorders.
Bristol Myers Squibb Co. has prepared and tested new Substituted benzimidazole compounds acting as Toll-like receptor 9 (TLR9) antagonists. They are reported to be useful for the treatment of fibrosis, metabolic dysfunction-associated steatohepatitis (MASH), chronic kidney disease, cancer, primary sclerosing cholangitis, idiopathic pulmonary fibrosis, inflammatory and autoimmune diseases.
Synnovation Therapeutics Inc. has patented phosphatidylinositol 3-kinase α (PI3K-α) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum and CLOVES syndrome (congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities).
Hemoshear Therapeutics Inc. has identified new 3-((1,1-dioxido-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)oxy)-2-fluoroacrylic acid derivatives acting as sodium-bile acid cotransporter (SLC10A1; NTCP) inhibitors.